PHASE 3 TRIAL OF SHR8058 EYE DROPS (PERFLUOROHEXYLOCTANE) CONDUCTED BY JIANGSU HENGRUI PHARMACEUTICALS IN THE PEOPLE'S REPUBLIC OF CHINA SHOWS STATISTICALLY SIGNIFICANT TOPLINE RESULTS

/PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free...

Related Keywords

China ,Germany ,United States ,Heidelberg ,Baden Wüberg ,Shanghai ,Cambridge ,Cambridgeshire ,United Kingdom ,Novaliq Gmb ,Hengrui Pharma ,Novaliq Eyesol ,Gmbh Co ,Jiangsu Hengrui Pharmaceuticals Co Ltd ,National Medical Products Administration ,Shanghai Stock Exchange ,Health Sciences ,Novaliq Inc ,Visual Analogue Scale ,Drug Evaluation ,Hopp Biotech ,Novaliq Gmbh ,